Given that dysregulation of IREα and XBP1s levels are associated with poor cancer patient survival and drug resistance [14–19] and IRE1’s kinase and endoribonuclease activities are required for generating XBP1s, IRE1α has become an attractive therapeutic targets for novel anticancer therapies. This evidence concerns the gene ERN1 and cancer.